Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC ibuprofen brand owned by Haleon (LSE/NYSE: HLN, GSK 2022 spinoff); Pfizer exited $3B+ stake early 2025 with ADA Seal for Advil Dual Action dental pain competing with Tylenol and Aleve for OTC analgesic market.
Advil is a global over-the-counter ibuprofen pain relief brand — owned by Haleon plc (LSE: HLN / NYSE: HLN), the consumer healthcare company spun off from GSK on July 18, 2022, with Pfizer completing its full stake exit in early 2025 for $3+ billion — providing consumers with 23+ ibuprofen-based product varieties for pain, headache, cold, and sleep management including Advil Extra Strength, Advil Rapid Release Gels, Advil PM, Advil Dual Action (ibuprofen + acetaminophen), and Children's Advil. Advil entered the US market in 1984 (the first OTC ibuprofen in America, considered the "most famous prescription-to-OTC switch in history") and generates approximately $800 million+ annually as one of Haleon's flagship brands alongside Sensodyne, Panadol, Centrum, and Theraflu. In September 2024, Advil Dual Action became the first OTC pain reliever to earn the American Dental Association (ADA) Seal of Acceptance for temporary management of acute dental pain.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.